{"id":"NCT00404352","sponsor":"Merck KGaA, Darmstadt, Germany","briefTitle":"REbif FLEXible Dosing in Early Multiple Sclerosis (MS)","officialTitle":"A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial of Rebif New Formulation (44 Microgram [Mcg] Three Times Weekly [Tiw] and 44 Mcg Once Weekly [ow]) in Subjects at High Risk of Converting to Multiple Sclerosis (REFLEX)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-11","primaryCompletion":"2010-08","completion":"2011-07","firstPosted":"2006-11-28","resultsPosted":"2012-09-24","lastUpdate":"2014-01-24"},"enrollment":517,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Multiple Sclerosis"],"interventions":[{"type":"DRUG","name":"RNF","otherNames":["Rebif"]},{"type":"DRUG","name":"RNF","otherNames":["Rebif"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"RNF 44 mcg three times weekly","type":"ACTIVE_COMPARATOR"},{"label":"RNF 44 mcg once weekly and placebo twice weekly for blinding","type":"ACTIVE_COMPARATOR"},{"label":"Placebo three times weekly","type":"PLACEBO_COMPARATOR"}],"summary":"The study is a 24 months randomized, double-blind, Placebo-controlled, multi-center clinical trial with an optional 12 months open label extension.\n\nThe primary objective of the study is to evaluate the effect of fetal bovine serum \\[FBS\\]-free/human serum albumin \\[HSA\\]-free formulation of Interferon \\[IFN\\] beta-1a (RNF) 44 microgram (three times weekly and once weekly) versus placebo on the time to conversion to McDonald multiple sclerosis (MS) criteria (2005) in subjects with a first clinical demyelinating event at high risk of converting to MS.\n\nThe main secondary objective of study is to evaluate the effect of RNF 44 microgram (three times weekly and once weekly) versus placebo on the \"Time to conversion to clinically definite MS (CDMS)\" in subjects with a first clinical demyelinating event at high risk of converting to MS.\n\nAt the end of 24 month double-blind core REFLEX trial, subjects who will not convert to CDMS and decide to receive open-label (OL) treatment will be enrolled into an open-label, 12 month extension period to evaluate the effect of RNF 44 mcg three times weekly treatment on the time to conversion to McDonald MS and time to conversion to CDMS.","primaryOutcome":{"measure":"Time to Conversion to Multiple Sclerosis (MS) According to the McDonald Criteria (2005)","timeFrame":"Various time points from randomization up to 24 months","effectByArm":[{"arm":"RNF 44 Mcg Three Times Weekly (Double Blind [DB] Population)","deltaMin":310,"sd":null},{"arm":"RNF 44 Mcg Once Weekly (DB Population)","deltaMin":182,"sd":null},{"arm":"Placebo (DB Population)","deltaMin":97,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"<0.001"},{"comp":"OG001 vs OG002","p":"0.008"},{"comp":"OG000 vs OG001","p":"0.009"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":24},"locations":{"siteCount":67,"countries":["Argentina","Australia","Austria","Belgium","Bulgaria","Canada","Croatia","Czechia","Estonia","Finland","France","Germany","Greece","Israel","Italy","Latvia","Lebanon","Morocco","Poland","Portugal","Romania","Russia","Saudi Arabia","Serbia","Slovakia","Spain","Turkey (TÃ¼rkiye)"]},"refs":{"pmids":["38560407","35274413","24413638","24292999","22146409"],"seeAlso":["http://www.mslifelines.com"]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":171},"commonTop":["Influenza like illness","Headache","Injection site erythema","Nasopharyngitis","Upper respiratory tract infection"]}}